Literature DB >> 24845387

Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis.

Maureen C Turina1, Joachim Sieper2, Nataliya Yeremenko3, Kristina Conrad2, Hildrun Haibel2, Martin Rudwaleit4, Dominique Baeten3, Denis Poddubnyy2.   

Abstract

Entities:  

Keywords:  Ankylosing Spondylitis; Outcomes research; Spondyloarthritis

Mesh：

Substances：

Year:  2014        PMID： 24845387     DOI： 10.1136/annrheumdis-2014-205506

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  29 in total

1.  Red blood cell distribution width: a potential maker estimating disease activity of ankylosing spondylitis.

Authors:  You-Fan Peng; Qiong Zhang; Ling Cao; Yang Liu; Dan Chen; Yu-Kun Sun; Zhao-Xia Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 3.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 4.  Mechanism of New Bone Formation in Axial Spondyloarthritis.

Authors:  Denis Poddubnyy; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2017-09       Impact factor: 4.592

Review 5.  Calprotectin in rheumatic diseases.

Authors:  Francesca Ometto; Lara Friso; Davide Astorri; Costantino Botsios; Bernd Raffeiner; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-01

Review 6.  Urolithiasis as an extraarticular manifestation of ankylosing spondylitis.

Authors:  Cengiz Korkmaz; Döndü Üsküdar Cansu; John A Sayer
Journal:  Rheumatol Int       Date:  2017-08-18       Impact factor: 2.631

Review 7.  The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward.

Authors:  Sjef van der Linden; Nurullah Akkoc; Matthew A Brown; Philip C Robinson; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

Review 8.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

9.  Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.

Authors:  Sevgi Baspinar; Mehmet Kırnap; Osman Baspınar; Oguzhan Sıtkı Dizdar; Derya Kocer
Journal:  Rheumatol Int       Date:  2016-07-21       Impact factor: 2.631

10.  Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis.

Authors:  Arzu Duran; Senol Kobak; Nazime Sen; Seniha Aktakka; Tennur Atabay; Mehmet Orman
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.